The level of evidence for the use of circulating tumor DNA monitoring, including ESR1 mutation, is improving, with prospective trials that have longitudinally evaluated the predictive and prognostic role of ctDNA in the metastastic setting, such as the PADA-1 trial [63] or the BIOLTALEE trial [76]. The gene discussed is ESR1; the disease is neoplasm.